Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology and ophthalmology. For more information, please visit: www.samsungbioepis.com.
To see our community guidelines, please visit: bit.ly/2l0yiI3
biosimilars, pharmaceutical, biopharmaceutical, biotechnology, regulatory affairs, clinical trials, research & development, novel biologic, oncology, immunology, ophthalmology, science, quality, innovation, healthcare